Flashnote 6 July 2018

EQUITIES	Marqueeldeas		
1211 HK Price (at 08:50, 05 Jul 2018 GMT)	Underperform HK\$47.75		
Valuation - PER	HK\$	34.00	
12-month target	HK\$	34.00	
Upside/Downside	%	-28.8	
12-month TSR	%	-28.3	
Volatility Index		Medium	
GICS sector	Automobiles & Components		
Market cap	HK\$m	112,408	
Market cap	US\$m	14,332	
30-day avg turnover	US\$m	32.8	
Number shares on issue	m	2,354	

Investment fundamentals

Year end 31 Dec		2017A	2018E	2019E	2020E
Revenue	bn	102.7	140.4	169.7	195.8
EBIT	bn	7.9	9.2	10.6	12.0
EBIT growth	%	-9.3	16.4	14.2	13.2
Reported profit	bn	4.1	4.7	5.8	6.9
EPS rep	Rmb	1.49	1.73	2.12	2.53
EPS rep growth	%	-24.1	16.3	22.3	19.4
PER rep	х	27.0	23.3	19.0	15.9
Total DPS	Rmb	0.14	0.17	0.21	0.25
Total div yield	%	0.3	0.4	0.5	0.6
ROA	%	4.9	4.9	5.0	5.2
ROE	%	7.2	7.9	9.0	9.9
EV/EBITDA	х	9.8	8.1	7.0	6.1
Net debt/equity	%	78.3	67.0	58.0	43.9
P/BV	х	2.0	1.9	1.7	1.6

1211 HK rel HSI performance, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, July 2018 (all figures in Rmb unless noted, TP in HKD)

Analysts

Macquarie Capital Limited Allen Yuan +86 21 2412 9009 allen.yuan@macquarie.com

allen.yuan@macquarie.com

Macquarie Capital Securities (Japan) Limited Janet Lewis, CFA +81 3 3512 78

Janet Lewis, CFA +81 3 3512 7856 janet.lewis@macquarie.com Hong Kong

BYD (1211 HK) Form a battery JV with Changan

Event

 On 5th July, BYD and Changan (200625 CH, HK\$7.78, Outperform, TP: HK\$9.3) inked a framework agreement on the strategic partnership in the power battery business (<u>LINK</u>).

Impact

Key messages about the cooperation: The two parties plan to establish a power battery JV "in the near future". The new JV will be based in Chongqing, with a total designed capacity of 10GWh (Phase I: 5-6GWh; Phase II: 4-5GWh). Further, Changan will invest in BYD's power battery business. Such a move reflects BYD's efforts to expand external battery sales and introduce strategic investors for its battery business. We believe such strategies could help enlarge the client base and ease the other OEMs' concerns on potential competition with BYD's own vehicles. That said, we remain cautious about the growth prospect of BYD's battery business due to the lack of a well-diversified client base – Changan only accounted for ~5% of the total new energy passenger vehicle sales in 2017. Further, it takes at least 2 years before such a partnership has a meaningful profit contribution to the listco.

Fig 1: China new energy passenger vehicle sales by auto group in 2017

	2017 sales (unit)	Market share
BYD Auto (incl. Denza)	113,716	20%
BAIC Group	101,078	18%
Geely Group (incl. Kangdi and Zhidou)	82,416	15%
SAIC Group	55,723	10%
Chery Group	30,308	5%
Jianghuai Automotive	29,809	5%
Changan Automobile Group	28,871	5%
Dongfeng Motor	10,032	2%
Others	106,659	19%
Total	558,612	100%
October 1 MO Macana de Dacasado I de 004	10	

Source: LMC, Macquarie Research, July 2018

- Why we are cautious on BYD (Hard sailing through mounting challenges, 4 May): We believe it is hard for BYD to benefit from the strong model cycle as the positives from the recovery in sales volume will be offset by the decline in subsidies, especially E-buses, dilution from entry trim models, rising battery material costs and heightened competition. Further, BYD's battery business is in a tough position in the context of industry oversupply, the lack of a well-diversified client base and its limited track record in the NCM (nickel-cobalt-manganese) battery segment. Gloomy prospects for the SkyRail business also weigh on the earnings outlook.
- Wait until August before building more short positions: In light of 1) the recent price correction; 2) the lack of negative catalysts before the announcement of the interim results; and 3) potential positive news headlines, such as the forming of the battery JV with Changan, we suggest investors to wait until August before building more short positons. While there is limited room for a miss for 2Q18 results as BYD has provided preliminary guidance, we believe the guidance for 3Q18 that will come along with the interim results will continue to disappoint, creating a major negative catalyst for the share price.

Action and recommendation

• We reiterate BYD as our key short idea in the China auto space.

Macquarie Research

Important disclosures:

Recommendation definitions

Macquarie - Australia/New Zealand Outperform – return >3% in excess of benchmark return Neutral – return within 3% of benchmark return Underperform – return >3% below benchmark return

Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield

Macquarie – Asia/Europe

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie – South Africa

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie - Canada

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

Macquarie - USA

Outperform (Buy) – return >5% in excess of Russell 3000 index return Neutral (Hold) – return within 5% of Russell 3000 index

return Underperform (Sell)– return >5% below Russell 3000

index return

Volatility index definition*

This is calculated from the volatility of historical price movements.

Very high-highest risk – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.

High – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

 $\ensuremath{\text{Medium}}$ – stock should be expected to move up or down at least 30–40% in a year.

Low-medium – stock should be expected to move up or down at least 25–30% in a year.

Low – stock should be expected to move up or down at least 15–25% in a year. * Applicable to Asia/Australian/NZ/Canada stocks only

Recommendations - 12 months

Note: Quant recommendations may differ from Fundamental Analyst recommendations

200625 CH vs CSI 300, & rec history

Sep-16

May-17

- C SI 300

Price Target

Dec-17

4500.00

4000.00

3500.00

3000.00

2500.00

Jul-18

200625

Feb-16

(all figures in HKD currency unless noted)

Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

EPS = adjusted net profit / efpowa*

ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average total assets ROE = adjusted net profit / average shareholders funds


Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

Recommendation proportions - For quarter ending 30 June 2018

······································							
	AU/NZ	Asia	RSA	USA	CA	EUR	
Outperform	52.87%	61.26%	48.86%	47.54%	69.86%	46.61%	(for global coverage by Macquarie, 3.51% of stocks followed are investment banking clients)
Neutral	34.10%	27.25%	36.36%	46.72%	21.92%	43.22%	(for global coverage by Macquarie, 2.10% of stocks followed are investment banking clients)
Underperform	13.03%	11.49%	14.77%	5.74%	8.22%	10.17%	(for global coverage by Macquarie, 0.00% of stocks followed are investment banking clients)





Note: Recommendation timeline – if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, July 2018

35.00

30.00

25.00

20.00

15.00

10.00

N

12-month target price methodology

1211 HK: HK\$34.00 based on a Sum of Parts methodology

200625 CH: HK\$9.90 based on a PER methodology

Company-specific disclosures:

1211 HK: Macquarie Capital Limited makes a market in the securities in respect of BYD Co. Ltd. Macquarie Capital Limited makes a market in the securities of BYD Co. Ltd. Macquarie Group Limited together with its affiliates beneficially owns 1% or more of the equity securities of Byd Co Ltd. Important disclosure information regarding the subject companies covered in this report is available at <u>www.macquarie.com/research/disclosures</u>.

Date	Stock Code (BBG code)	Recommendation	Target Price
04-五月-2018	1211 HK	Underperform	HK\$34.00
02-十一月-2017	1211 HK	Underperform	HK\$50.90
11-四月-2017	1211 HK	Neutral	HK\$47.90
20-一月-2017	1211 HK	Neutral	HK\$41.50
03-十一月-2016	1211 HK	Neutral	HK\$48.00
31-五月-2016	1211 HK	Underperform	HK\$26.10
22-三月-2016	1211 HK	Underperform	HK\$24.00

Target price risk disclosures:

1211 HK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. Government policy related to new energy vehicles also has a big impact. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

200625 CH: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

Macquarie Research

Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities. **General disclaimers:**

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie Equities South Africa (Pty) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Members of the Macro Strategy team are Sales & Trading personnel who provide desk commentary that is not a product of the Macquarie Research department or subject to FINRA Rule 2241 or any other regulation regarding independence in the provision of equity research. Country-specific disclaimers:

Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organisation of the Australian Securities Exchange. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd. a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd., a (i) member of the Investment Industry Regulatory Organization of Canada and the Canadian Investor Protection Fund, and (ii) participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. This research is distributed in the United States, as third party research by Macquarie Capital Markets North America Ltd., which is a registered broker-dealer and member of Financial Industry Regulatory Authority and the Securities Investor Protection Corporation. Macquarie Capital Markets North America Ltd. accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd. in the United States and sent to US persons. Any US person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd. should do so with Macquarie Capital Markets North America Ltd. This research is intended for distribution in the United States only to major Institutional Investors (as such term is defined in SEC 15a-6 and Section 15 of the Securities Exchange Act of 1934, as amended) and is not intended for the use of any person or entity that is not a major institutional investor. Research analysts of Macquarie Capital Markets Canada Ltd. are not registered/gualified as research analysts with FINRA. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd. is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Conduct Authority (No. 193905). and in Germany by BaFin. France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. The recipient of this report shall not engage in any activities which may give rise to potential conflicts of interest to the report. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Macquarie may be in past one year or now being an Issuer of Structured Warrants on securities mentioned in this report. **Thailand**: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thaiiod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=MDIS03002001000000&serviceId=SDIS03002 001000. South Africa: In South Africa, research is issued and distributed by Macquarie Equities South Africa (Pty) Ltd, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital

Macquarie Research

BYD (1211 HK)

(Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie Equities South Africa (Pty) Ltd and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. **United States**: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered reports of www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019.

© Macquarie Group

Equities

Asia Research

Head of Equity Research Jake Lynch (Asia - Head) (852) 3922 3583 Hiroyuki Sakaida (Japan - Head) (813) 3512 6695 Conrad Werner (ASEAN – Head) (65) 6601 0182 Automobiles, Auto Parts Janet Lewis (China, Japan) (813) 3512 7856 Allen Yuan (China) (8621) 2412 9009 James Hong (Korea) (822) 3705 8661 Amit Mishra (India) (9122) 6720 4084 **Banks and Financials** Scott Russell (Asia) (852) 3922 3567 Dexter Hsu (China, Taiwan) (8862) 2734 7530 Keisuke Moriyama (Japan) (813) 3512 7476 Chan Hwang (Korea) (822) 3705 8643 Suresh Ganapathy (India) Jayden Vantarakis (Indonesia) (9122) 6720 4078 (6221) 2598 8310 Anand Pathmakanthan (Malaysia) (603) 2059 8833 Gilbert Lopez (Philippines) (632) 857 0892 (65) 6601 0836 Ken Ang (Singapore) **Basic Materials** Polina Diyachkina (Asia, Japan) (813) 3512 7886 Yasuhiro Nakada (Japan) (813) 3512 7862 Anna Park (Korea) (822) 3705 8669 (9122) 6720 4093 (6221) 2598 8310 Sumangal Nevatia (India) Javden Vantarakis (Indonesia) Farrah Aqlima (Malaysia) (603) 2059 8987 Conglomerates David Ng (China, Hong Kong) (852) 3922 1291 Conrad Werner (Singapore) (65) 6601 0182 (632) 857 0892 Gilbert Lopez (Philippines) Consumer, Gaming Linda Huang (Asia) (852) 3922 4068 (852) 3922 1130 Zibo Chen (China, Hong Kong) Terence Chang (China, Hong Kong) (852) 3922 3581 Sunny Chow (China, Hong Kong) Stella Li (China, Taiwan) (852) 3922 3768 (8862) 2734 7514 Leon Rapp (Japan) (813) 3512 7879 Kwang Cho (Korea) (822) 3705 4953 Amit Šinha (India) (9122) 6720 4085 Karisa Magpayo (Philippines) Chalinee Congmuang (Thailand) (632) 857 0899 (662) 694 7993 Robert Pranata (Indonesia) (6221) 2598 8366 Richardo Walujo (Indonesia) (6221) 2598 8369

Emerging Leaders

Emerging Leaders	
Jake Lynch (Asia)	(852) 3922 3583
Kwang Cho (Korea)	(822) 3705 4953
Corinne Jian (Greater China)	(8862) 2734 7522
Conrad Werner (ASEAN)	(65) 6601 0182
Bo Denworalak (Thailand)	(662) 694 7774
Infrastructure, Industrials, 1	Fransportation
Patrick Dai (China)	(8621) 2412 9082
Eric Zong (China, Hong Kong)	(852) 3922 4749
Kunio Sakaida (Japan)	(813) 3512 7873
James Hong (Korea)	(822) 3705 8661
Corinne Jian (Taiwan)	(8862) 2734 7522
Inderjeetsingh Bhatia (India)	(9122) 6720 4087
Azita Nazrene (ASEAN)	(65) 6601 0560
Internet, Media and Softwar	е
Wendy Huang (Asia)	(852) 3922 3378
Marcus Yang (Greater China)	(8862) 2734 7532
David Gibson (Japan)	(813) 3512 7880
Alankar Garude (India)	(9122) 6720 4134
Oil, Gas and Petrochemical	s
Aditya Suresh (Asia)	(852) 3922 1265
Anna Park (Asia)	(822) 3705 8669
Polina Diyachkina (Japan)	(813) 3512 7886
Yasuhiro Nakada (Japan)	(813) 3512 7862
Corinne Jian (Taiwan)	(8862) 2734 7522
Ben Shane Lim (Malaysia)	(603) 2059 8868
Yupapan Polpornprasert (Thailand)	(662) 694 7729
Pharmaceuticals and Health	hcare
Corinne Jian (China)	(8862) 2734 7522
Alankar Garude (India)	(9122) 6720 4134
Richardo Walujo (Indonesia)	(6221) 259 88 369
Property, REIT	
Tuck Yin Soong (Asia, Singapore)	(65) 6601 0838
David Ng (China, Hong Kong)	(852) 3922 1291
Kelvin Tam (China)	(852) 3922 1181
Catherine Li (Hong Kong)	(852) 3922 1161
Keisuke Moriyama (Japan)	(813) 3512 7476
Tomoyoshi Omuro (Japan)	(813) 3512 7474
Abbiobel Benadrei (India)	(9120) 6720 498

Technology

	reenneregy					
(852) 3922 3583 (822) 3705 4953 (8862) 2734 7522 (65) 6601 0182 (662) 694 7774 Transportation (8621) 2412 9082 (852) 3922 4749 (813) 3512 7873	Damian Thong (Asia, Japan) Allen Chang (Greater China) Jeffrey Ohlweiler (Greater China) Chris Yu (Greater China) Kaylin Tsai (Greater China) Lynn Luo (Greater China) Patrick Liao (Greater China) Verena Jeng (Greater China) Daniel Kim (Korea) Abhishek Bhandari (India)	(813) 3512 7877 (852) 3922 1136 (8862) 2734 7512 (8621) 2412 9024 (8862) 2734 7523 (8862) 2734 7523 (8862) 2734 7515 (852) 3922 3766 (822) 3705 8641 (9122) 6720 4088				
(822) 3705 8661 (8862) 2734 7522 (9122) 6720 4087	Farrah Aqlima (Malaysia) (603) 2059 8987 Telecoms					
(65) 6601 0560 e	Allen Chang (Greater China) Prem Jearajasingam (ASEAN) Kervin Sisayan (Philippines)	(852) 3922 1136 (603) 2059 8989 (632) 857 0893 (6321) 2508 8365				
(852) 3922 3378 (8862) 2734 7532	Nathania Nurhalim (Indonesia) (6221) 2598 8365 Utilities, Renewables					
(813) 3512 7880 (9122) 6720 4134 S	Hiroyuki Sakaida (Japan) Patrick Dai (China) Inderjeetsingh Bhatia (India) Karisa Magpayo (Philippines)	(813) 3512 6695 (8621) 2412 9082 (9122) 6720 4087 (632) 857 0899				
(852) 3922 1265 (822) 3705 8669	Karisa Magpayo (Philippines) (632) 857 0899 Quantitative, CPG					
(813) 3512 7886 (813) 3512 7862 (8862) 2734 7522 (603) 2059 8868 (662) 694 7729	Gurvinder Brar (Global) John Conomos (Asia) Alvin Chao (Asia) Tracy Chow (Asia) YingYing Hou (Asia)	(44 20) 3037 4036 (612) 8232 5157 (852) 3922 1108 (852) 3922 4285 (852) 3922 5422				
(8862) 2734 7522	Strategy, Country					
(6862) 2734 7522 (9122) 6720 4134 (6221) 259 88 369	Viktor Shvets (Asia, Global) David Ng (China, Hong Kong) Hiroyuki Sakaida (Japan) Chan Hwang (Korea)	(852) 3922 3883 (852) 3922 1291 (813) 3512 6695 (822) 3705 8643 (8862) 2734 7512 (9122) 6720 4087 (6221) 2598 8310 (603) 2059 8833 (632) 857 0892 (65) 6601 0182				
(65) 6601 0838 (852) 3922 1291 (852) 3922 1181 (852) 3922 1161 (813) 3512 7476 (813) 3512 7474 (9122) 6720 4088	Jeffrey Ohlweiler (Taiwan) Inderjeetsingh Bhatia (India) Jayden Vantarakis (Indonesia) Anand Pathmakanthan (Malaysia) Gilbert Lopez (Philippines) Conrad Werner (ASEAN, Singapore)					
(603) 2059 8986 (632) 857 0893 (65) 6601 0760	Find our research at Macquarie: www.macquarieresearch.com Thomson: www.thomson.com/financial Reuters: www.knowledge.reuters.com Bloomberg: MAC GO Factset: http://www.factset.com/home.aspx CapitallQ www.capitaliq.com Email macresearch@macquarie.com for access					

Asia Sales

Denise Soon (Malaysia)

Regional Heads of Sales

(603) 2059 8845

Regional Heads of Sales cont'd

Paul Colaco (San Francisco) Angus Kent (Thailand) Ben Musgrave (UK/Europe) Christina Lee (UK/Europe) Sales Trading

Abhishek Bhandari (India)

Roy Chen (Singapore)

Aiman Mohamad (Malaysia) Kervin Sisayan (Philippines)

Adam Zaki (Asia)

Stanley Dunda (Indonesia)

(1 415) 762 5003 (662) 694 7601 (44 20) 3037 4882 (44 20) 3037 4873

(852) 3922 2002 (6221) 515 1555

Sales Trading cont'd

Suhaida Samsudin (Malaysia)	(603) 2059 8888
Michael Santos (Philippines)	(632) 857 0813
Chris Reale (New York)	(1 212) 231 2555
Marc Rosa (New York)	(1 212) 231 2555
Justin Morrison (Singapore)	(65) 6601 0288
Daniel Clarke (Taiwan)	(8862) 2734 7580
Brendan Rake (Thailand)	(662) 694 7707
Mike Keen (UK/Europe)	(44 20) 3037 4905